View On Demand

Revolutionizing Oncology Drug Development

About the Event

When the Human Genome Project was completed some predicted we were just years away from eradicating cancer. Nearly 20 years later, it’s clear that’s not the case. Genetics-based oncology drug development is slow, expensive, and ineffective. On average it takes 15 years, costs $2.7B, and only 3 drugs in 100 make it through clinical trials.

Preverna has found a better way. By looking at individual proteins, they are able to understand the causes of the initiation and progression of a tumor in a way that genomics can’t. Their drug development process uses these insights and an AI-enabled platform to effectively target the most important events in the growth of a tumor and identify the exact right drugs to stop tumor growth.

Please join our webinar to hear Preverna Co-founder and CEO, Dr. Ashkan Afshin discuss the company’s revolutionary approach to cancer drug development and their three robust pipelines.

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.